• Cryptocurrencies
  • Prediction Markets
  • News
  • Agentic Trading
  • Blog
  • Leagues

Search Cryptocurrencies

Trending Cryptocurrencies

CoinRithm

Company

Legal Entity
Bees-x Limited
Company Number
13308136
Incorporated In
England and Wales
Registered Office
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is an information and research service operated by Bees-x Limited. It is not authorised by the Financial Conduct Authority (FCA) to carry on regulated activities, and nothing on this site is financial advice.

Explore

CryptocurrenciesPrediction MarketsNewsBlogAgent ArenaLeagues

Features

DashboardMock TradeAgentic TradingPortfolioWatchlistSettings

Company

About UsMethodologyTerms of UsePrivacy PolicyCookie PolicyDisclaimer

Support

Contact SupportFAQDeveloper kitMCP docs

Socials

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. All rights reserved.
Get it on Google PlayDownload on the App Store
  • Home
  • MarketsPrediction Markets
  • News
  • Dashboard
  1. Prediction Markets
  2. Health & Medicine
  3. When will the FDA reclassify BPC-157 to Category 1?
When will the FDA reclassify BPC-157 to Category 1?

When will the FDA reclassify BPC-157 to Category 1?

4.0% (24h)Health & MedicineOne-Off19d
KalshiKalshiCheck availabilityKYC required2% fee
Current implied probability
Before July
Before July 5%+4.0%
Leader of 6 outcomes
Market quality

28 / 100

Low quality
24h Volume

$0.2

Liquidity

$119.8

Low liquidity
Bid / Ask

1.0% / 6.0%

Spread

500.0%

Wide spread
Market data

Updated 5 minutes ago

Mar 24, 26, 2:00 PMJul 1, 26, 3:59 AM

Trends

Outcome24hChance

Selected outcome

Before July5%

Rules

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.

Related Markets

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

$170.1K
Yes: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

$19.2K
Yes: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

$10.1K
Yes: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

$1.5K
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

$533.9
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

$159.1
2025: 0%Manifold MarketsMANIFOLD MARKETS

Active in these topics

BitcoinBTC$62,782.97+1.81%EthereumETH$1,656.87+1.13%SolanaSOL$65.12+0.91%DogecoinDOGE$0.085+1.08%XRPXRP$1.12-0.05%BNBBNB$597.14+1.48%

Related News

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Rules

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.